From the day on from the former U.S. president Trump was given a preliminary antibody cocktail treatment after a test revealed that he is COVID positive, Regeneron’s antibody cocktail became the topic of current interest for everybody. Before everything else, to begin with, Regeneron Pharmaceuticals, Inc., an American biotechnology company, after months of incredibly hard work, developed a Casirivimab and imdevimab injection, which is a cocktail of two monoclonal antibodies, specifically designed to impede the SARS-CoV-2, the fatal virus that causes coronavirus. In the current times, the third wave of coronavirus across different regions of the world helped us all recall that we are still halfway through the global pandemic.
The global crisis of COVID-19 has shattered more than 2.23 million lives as of now, and as new cases persist to surge each day, there is an emerging concern about many more lives at stake in the forthcoming time. Whilst, the majority of the people who are infected with the SARS-CoV-2 novel coronavirus heal and get better on their own, there are many others who require emergency medical care within a few days of an earlier stage of infection. After hospitalization, these patients might deteriorate briskly, specifically if they have to be intubated due to the acute respiratory distress caused by the fatal virus.
At the same time, several treatment options are also developed and made accessible to the general population across the world, especially to treat the most seriously ill patients. Among all of which, Regeneron’s developed antibody cocktail, REGN-COV2, successfully received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA), although it is yet going through phase III human trials.
Regeneron’s physicians and scientists have gone through thousands of fully-human antibodies in order to develop REGN-COV2, and lastly selected two antibodies, one from the human survivor who recovered from COVID-19 and the other from the mice, which have been genetically modified to have a human immune system. The REGN-COV2 has the potential to fasten to the pivotal receptor binding domain of the virus's spike protein, which favorably alleviates the capacity of mutant viruses to elude the medical treatment and safeguards against the deadly virus.
However, there is yet a lot of confusion and skepticism out there about the safety and effectiveness of this antibody cocktail and what it can and cannot do. After all the latest tests and trials, Regeneron claimed that the antibody cocktail, REGN-COV2, successfully diminishes the viral load of the patients as well as also helps in alleviating the symptoms in non-hospitalized patients with COVID-19. Ultimately, what the antibody cocktail is doing to a COVID positive patient’s body is giving a boost to the immune system, helping mitigate the symptoms faster, and potentially, it can avoid the patient’s need to go to the hospital. So, one can easily infer from the results that the antibody cocktail, thus far, is showing promising results and is likely to accelerate the recovery process of the patients.
In spite of everything, there are still 1% of the adverse events based on the number of patients they recruited for the trial, which included additional treatments required for patients, and even termination of the infusion. Owing to which, it could be said that the antibody cocktail still is risky, and if given to hundreds or thousands of patients, worldwide, it might have heavy adverse repercussions. Coming to the bottom line, Regeneron’s developed antibody cocktail successfully represented that it surely has some preventive effects against the COVID virus, which concludes that it can be given as a preventive medication to the patients. Further, it is expected that the antibody cocktail will soon receive EUA along with proper limitations and restrictions, and it will not be accessible to everybody.
Following this, Regeneron signed a new pact with the U.S. government to deliver 1.25 million finished doses of the casirivimab and imdevimab antibody cocktail for the treatment of non-hospitalized COVID-19 patients, which will most probably be supplied by June 2021. A few other giant pharmaceutical players in the market also aimed their focus on the development of an antibody cocktail, which might act as a preventive medication for the SARS-CoV-2 virus. For instance, Eli Lilly, an American pharmaceutical company, believes that its monoclonal antibody, bamlanivimab, could be an alternative not just to operate and cure COVID-19 but to help prevent it in defined circumstances.
Moreover, AstraZeneca, a British-Swedish multinational pharmaceutical and biopharmaceutical company, also initiated its late-stage trials of an experimental monoclonal antibody combination drug, known as AZD7442, anticipating that it could be utilized as a preventive measure to treat SARS-CoV-2 virus in people who are at high risk for up to 12 months.